EUVIMEDEUVIMED entdecken
Open Access

Discontinuation of Cholinesterase Inhibitors Following Initiation of Memantine and Admission to Long-Term Care Among Older Adults

Yu-Chien Lee, Sandra M Shi, Stephanie M Sison, Chan Mi Park, Gahee Oh, Sohyun Jeong, Ellen P McCarthy, Dae Hyun Kim

JAMA Network Open · 2024

DOI: 10.1001/jamanetworkopen.2024.45878 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA Network Open, 2024. Verfasst von Yu-Chien Lee und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Family Medicine, Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan. Hauptthemen laut MEDLINE: Memantine, Cholinesterase Inhibitors, Long-Term Care, Dementia. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIA NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Discontinuing cholinesterase inhibitors when initiating memantine in patients with dementia may be reasonable to reduce treatment burden, costs, and the risk of adverse drug events.

Objective

To assess the association of cholinesterase inhibitor discontinuation on long-term care institutionalization among older adults with dementia who initiate memantine. Design, Setting, and Participants This retrospective propensity score-matched cohort study used Medicare claims data from January 2014 to December 2019. Participants included fee-for-service Medicare beneficiaries with dementia. Data were analyzed from September 2021 to August 2024. Exposures Discontinuation vs continuation of cholinesterase inhibitor. Main Outcomes and Measures The primary outcome was 1-year long-term care institutionalization-free days. Secondary outcomes include all-cause death and adverse drug events over 1 year. We performed subgroup analyses based on age, sex, dementia type (Alzheimer disease vs other), frailty, and dementia severity (mild vs moderate or severe) based on claims-based algorithms. The primary outcome was analyzed using nonparametric restricted mean survival time analysis.

Results

Among 16 292 beneficiaries who initiated memantine, 1820 (11.2%) discontinued cholinesterase inhibitors. In the propensity score-matched cohort of 3612 beneficiaries, the mean (SD) age was 80.7 (6.7) years, 2261 (62.6%) were female, and 1989 (55.0%) had a diagnosis of Alzheimer disease. Over 1 year, long-term care institutionalization occurred in 51 of 1806 beneficiaries (2.8%) who discontinued cholinesterase inhibitors (3.4 per 100 person-years) and 62 of 1806 beneficiaries (3.4%) who continued (4.1 per 100 person-years). There was no statistically significant difference in the 1-year mean institutionalization-free days between discontinuation and continuation groups (360.6 [95% CI, 359.3 to 362.0] days vs 359.1 [95% CI, 357.5 to 360.6] days; mean difference, 1.5 [95% CI,−0.5 to 3.6] days). The mean difference in the long-term care institutionalization-free days did not differ by age category, sex, dementia type, frailty, or dementia stage. Individuals who discontinued had a lower rate of fall-related injury (0.9 vs 2.0 per 100 person-years; hazard ratio [HR], 0.47 [95% CI, 0.25 to 0.88]). There was no difference between the discontinuation and continuation groups in all-cause death (10.4 vs 11.6 per 100 person-years; HR, 0.89 [95% CI, 0.72 to 1.10]). Conclusions and Relevance In this study, discontinuing cholinesterase inhibitors upon memantine initiation was not associated with an increased risk of long-term care institutionalization but with a lower risk of fall-related injury among older adults with dementia. These findings offer valuable insights for clinicians aiming to reduce treatment burden in this population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MemantineCholinesterase InhibitorsLong-Term CareDementiaHumansFemaleMaleAgedAged, 80 and overRetrospective StudiesUnited StatesMedicarePropensity ScoreWithholding Treatment

Substanzen

MemantineCholinesterase Inhibitors

Autor:innen und Institutionen

  • Department of Family Medicine, Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan.
  • Marcus Institute for Aging Research, Hebrew SeniorLife, Boston, Massachusetts.
  • Department of Medicine, University of Massachusetts Chan Medical School, Worcester.
  • Department of Pharmacy Practice, Massachusetts College of Pharmacy and Health Science, Boston.
  • Division of Gerontology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts.

Förderung

  • NIA NIH HHS

Zitieren

APA

Lee, Y. C., Shi, S. M., Sison, S. M., Park, C. M., Oh, G., Jeong, S., McCarthy, E. P., & Kim, D. H. (2024). Discontinuation of Cholinesterase Inhibitors Following Initiation of Memantine and Admission to Long-Term Care Among Older Adults. JAMA Network Open. https://doi.org/10.1001/jamanetworkopen.2024.45878

Vancouver

Lee YC, Shi SM, Sison SM, Park CM, Oh G, Jeong S, et al. Discontinuation of Cholinesterase Inhibitors Following Initiation of Memantine and Admission to Long-Term Care Among Older Adults. JAMA Network Open. 2024. doi:10.1001/jamanetworkopen.2024.45878

BibTeX
@article{Lee2024,
  author = {Lee, Yu-Chien and Shi, Sandra M and Sison, Stephanie M and Park, Chan Mi and Oh, Gahee and Jeong, Sohyun and McCarthy, Ellen P and Kim, Dae Hyun},
  title = {Discontinuation of Cholinesterase Inhibitors Following Initiation of Memantine and Admission to Long-Term Care Among Older Adults},
  journal = {JAMA Network Open},
  year = {2024},
  doi = {10.1001/jamanetworkopen.2024.45878}
}
Kostenlos starten →